At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Triheptanoindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial
In Brief
A Phase 1 clinical trial evaluating Triheptanoin for Epilepsy and 6 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, GLUT1DS1, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders, Glucose Transport Defect, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome
CountriesUnited States
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedFeb 2, 2017
Enrollment StartMar 29, 2017
Primary CompletionDec 22, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.4 years ago
Interventions
Triheptanoindrug
Triheptanoin will be administered for 7 days 4 times daily.